Trials / Completed
CompletedNCT00852826
Evaluation of a Hemostatic and Sealing Agent to Prevent Surgical Complications After Axillary Lymphadenectomy
Value of a Hemostatic and Sealing Agent for Preventing Seroma After Axillary Lymphadenectomy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Hospital Universitario Virgen de la Arrixaca · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was intended to assess the value of a hemostatic and sealing agent, a collagen sponge coated with human coagulation factors (fibrinogen and thrombin) (TachoSil®), for decreasing occurrence of seroma after axillary lymphadenectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Standard axillary lymphadenectomy | Standard axillary lymphadenectomy |
| PROCEDURE | Collagen sponge coated with human coagulation factors | Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls |
Timeline
- Start date
- 2008-01-01
- Completion
- 2008-11-01
- First posted
- 2009-02-27
- Last updated
- 2009-02-27
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00852826. Inclusion in this directory is not an endorsement.